Based on the key indicators related to Pharvaris' liquidity, profitability, solvency, and operating efficiency, Pharvaris BV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Pharvaris' Other Stockholder Equity is comparatively stable compared to the past year. Net Invested Capital is likely to gain to about 403.3 M in 2024, despite the fact that Net Debt is likely to grow to (371.4 M). Key indicators impacting Pharvaris' financial strength include:
The essential information of the day-to-day investment outlook for Pharvaris includes many different criteria found on its balance sheet. An individual investor should monitor Pharvaris' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Pharvaris.
Net Income
(95.83 Million)
Pharvaris
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Issuance Of Capital Stock
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Change To Inventory
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Net Invested Capital
Total Current Assets
Accumulated Other Comprehensive Income
Net Working Capital
Common Stock
Net Tangible Assets
Other Current Assets
Capital Stock
Property Plant And Equipment Net
Other Assets
Property Plant And Equipment Gross
Property Plant Equipment
Capital Lease Obligations
Inventory
Tax Provision
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Gross Profit
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Pharvaris Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pharvaris' financial statements are interrelated, with each one affecting the others. For example, an increase in Pharvaris' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pharvaris' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharvaris BV. Check Pharvaris' Beneish M Score to see the likelihood of Pharvaris' management manipulating its earnings.
Pharvaris Stock Summary
Pharvaris competes with Pmv Pharmaceuticals, Eliem Therapeutics, MediciNova, PepGen, and Molecular Partners. Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company was incorporated in 2015 and is based in Leiden, the Netherlands. Pharvaris is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Pharvaris' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Pharvaris's current stock value. Our valuation model uses many indicators to compare Pharvaris value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharvaris competition to find correlations between indicators driving Pharvaris's intrinsic value. More Info.
Pharvaris BV is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Pharvaris' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Pharvaris by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Pharvaris BV Systematic Risk
Pharvaris' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharvaris volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Pharvaris BV correlated with the market. If Beta is less than 0 Pharvaris generally moves in the opposite direction as compared to the market. If Pharvaris Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharvaris BV is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharvaris is generally in the same direction as the market. If Beta > 1 Pharvaris moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Pharvaris Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pharvaris' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pharvaris growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Pharvaris help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pharvaris BV. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pharvaris BV based on widely used predictive technical indicators. In general, we focus on analyzing Pharvaris Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharvaris's daily price indicators and compare them against related drivers.
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.